RAILY AESMED released its interim results, with a loss attributable to shareholders of 7.57 million yuan, an increase of 368.15% year-on-year
RAILY AESMED released its interim results for the period ending June 30, 2025, reporting revenue of RMB 84.598 million, a year-on-year decrease of 27.99%; loss attributable to equity holders of the parent company was RMB 7.57 million, a year-on-year increase of 368.15%; loss per share was 1.36 cents. Revenue from medical beauty services was approximately RMB 74.90 million, a year-on-year decrease of 9.7%, mainly due to a reduction in the number of active customers caused by intense competition
According to the Zhitong Finance APP, RAILY AESMED (02135) released its interim results for the six months ending June 30, 2025, reporting revenue of HKD 84.598 million, a year-on-year decrease of 27.99%; the loss attributable to the parent company was HKD 7.57 million, a year-on-year increase of 368.15%; the loss per share was 1.36 cents.
During the reporting period, our revenue from medical beauty services was approximately HKD 74.90 million, a decrease of about 9.7% compared to the medical beauty service revenue of approximately HKD 83.00 million for the six months ending June 30, 2024. This decline was due to the increase in average transaction value not offsetting the impact of a decrease in the number of active customers caused by intense industry competition, leading to a reduction in revenue from minimally invasive beauty services and skin beauty services
